期刊
BEHAVIOURAL PHARMACOLOGY
卷 33, 期 1, 页码 2-14出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FBP.0000000000000603
关键词
anxiety; cannabinoids; depression; endocannabinoid system; rat; vanilloids
资金
- National Council for Scientific and Technological Development (CNPq)
- CNPq [406122/20164]
- Sao Paulo Research Foundation (FAPESP) [2017/24304-0]
- Coordination for Higher Education Staff Development (CAPES)
The TRPV1 channel plays a crucial role in pain, inflammation, and body temperature regulation, and is expressed in specific brain regions. TRPV1 blockers show promising effects in animal models of anxiety, panic, depression, and neurodevelopmental disorders.
The transient receptor potential vanilloid-1 channel (TRPV1) is responsible for decoding physical and chemical stimuli. TRPV1 is activated by capsaicin (a compound from chili peppers), heat (above 43 degrees C) and acid environment, playing a major role in pain, inflammation and body temperature. Molecular and histological studies have suggested TRPV1 expression in specific brain regions, where it can be activated primarily by the endocannabinoid anandamide, fostering studies on its potential role in psychiatric disorders. TRPV1 blockers are effective in various animal models predictive of anxiolytic and antipanic activities, in addition to reducing conditioned fear. In models of antidepressant activity, these compounds reduce behavioral despair and promote active stress-coping behavior. TRPV1 blockers also reduce the effects of certain drugs of abuse and revert behavioral changes in animal models of neurodevelopmental disorders. The main limiting factor in developing TRPV1 blockers as therapeutic agents concerns their effects on body temperature, particularly hyperthermia. New compounds, which block specific states of the channel, could represent an alternative. Moreover, compounds blocking both TRPV1 and the anandamide-hydrolyzing enzyme, fatty acid amide hydrolase (FAAH), termed dual TRPV1/FAAH blockers, have been investigated with promising results. Overall, preclinical studies yield favorable results with TRPV1 blockers in animal models of psychiatric disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据